REGENXBIO INC
RGNXNASDAQ🏆 #2253 by market capUS Equity
$133.93▼ $5.93 (−4.43%)
Simulated price1h—
24h▼ 4.4%
7d▲ 1176.1%
14d▲ 1295.1%
30d▲ 949.2%
1y▲ 1559.6%
🏦Market Cap
$703M
Small Cap
📈Revenue Growth (YoY)
+12.0%
Healthy
📊Gross Margin
86.4%
High
💵FCF Margin
18.7%
Healthy
⚖️P/S Ratio
4.0x
Fair
Otter Score
46
Weak
Trading Snapshot
- Day Range
- $132.85 – $135.59
- 52-Week Range
- $5.46 – $16.19
- Volume
- $1.94B
- Avg Volume
- $2.42B
- Shares Outstanding
- 63.3M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $177M
- Last Q Revenue
- $43M
- P/E Ratio
- —
- P/S Ratio
- 4.0x
- EPS (TTM)
- $-3.79
- Dividend Yield
- —
Why Investors Own RGNX
- ✓High-growth profile — revenue up +59.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$177M▲ +55.6% YoY
Gross Margin (TTM)
38.6%▲ +0.9% YoY
Operating Income (TTM)
$61M▲ +55.6% YoY
Free Cash Flow (TTM)
$11M▲ +55.6% YoY
About REGENXBIO INC
A company profile for REGENXBIO INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Price Target
ⓘAverage Target
$158.51
▲ +18.4% Upside
High Target$197.43
Low Target$143.92
Based on 23 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
REGENXBIO INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift RGNX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
REGENXBIO INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.